Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
As only the son had the major clinical manifestations of ALPS-FAS, miR-21-3p should be investigated as playing a critical role in ALPS physiopathology, including the development of lymphoma.
|
27060458 |
2016 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Localized Store-Operated Calcium Influx Represses CD95-Dependent Apoptotic Effects of Rituximab in Non-Hodgkin B Lymphomas.
|
26202984 |
2015 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Our principal findings are that FAS mutations have a clinical penetrance of <60%, elevated serum vitamin B12 is a reliable and accurate biomarker of ALPS-FAS, and the major causes of morbidity and mortality in these patients are the overwhelming postsplenectomy sepsis and development of lymphoma.
|
24398331 |
2014 |
Lymphoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In normal and lymphoma B cells, this correlated to increased CD95 membrane expression, enhanced DISC activity and engagement of the mitochondrial death pathway via Bid cleavage, although the latter occurred less efficiently in B-NHLr.
|
19751723 |
2009 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis.
|
17277134 |
2007 |
Lymphoma
|
0.400 |
GeneticVariation
|
group |
LHGDN |
A role for the Fas/FasL system in modulating genetic susceptibility to T-cell lymphoblastic lymphomas.
|
17545588 |
2007 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Repression of TCL1 in GC B cells facilitates FAS-mediated apoptosis and prevents lymphoma formation.
|
17548807 |
2007 |
Lymphoma
|
0.400 |
GeneticVariation
|
group |
LHGDN |
Development of lymphoma in Autoimmune Lymphoproliferative Syndrome (ALPS) and its relationship to Fas gene mutations.
|
15160902 |
2004 |
Lymphoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A loss of FAS (CD95) function has been proposed to constitute an important step in early mucosa-associated lymphoid tissue (MALT) lymphoma development and FAS mutations have been recognized in malignant lymphomas, in particular at extranodal sites.
|
14982861 |
2004 |
Lymphoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Development of lymphoma in Autoimmune Lymphoproliferative Syndrome (ALPS) and its relationship to Fas gene mutations.
|
15160902 |
2004 |
Lymphoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Somatic Fas mutations causing truncation of the Fas receptor were identified in two MALT-type lymphomas.
|
12950026 |
2003 |
Lymphoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We demonstrate that CD95 mutations occur at low frequency in NHL tumors, however, surface expression of the CD95 protein varies with the subtype of lymphoma.
|
11697638 |
2002 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Accordingly, cell shrinkage did not induce apoptosis in CD95 receptor-negative lymphoma L1210 cells.
|
11598798 |
2001 |
Lymphoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Fas (CD95, APO-1) mutations were found in autoimmune diseases and some lymphomas, suggesting impairment of Fas-mediated cell death signaling that may cause tumor development.
|
11454987 |
2001 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We conclude that the diagnosis of a FAS-FAS-L deficiency should be considered in children with an otherwise unexplained atypical lymphoproliferation and that a diagnosis of lymphoma in patients with functional FAS deficiency should be made with considerable reservation.
|
10403307 |
1999 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Recently, the Fas (CD95/APO-1)/Fas ligand system has been identified as a key regulator of apoptosis in some types of lymphoma cell lines.
|
9815617 |
1997 |
Lymphoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Search for rearrangements and/or allelic loss of the fas/APO-1 gene in 101 human lymphomas.
|
7572793 |
1995 |
Lymphoma
|
0.400 |
Biomarker
|
group |
GENOMICS_ENGLAND |
|
|
|